Clevidipine is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. It is available as injectable emulsion for intravenous use. MedsAcross supplies Clevidipine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Cleviprex is indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. Cleviprex is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable.
Source: US FDA prescribing information
Clevidipine is a dihydropyridine L-type calcium channel blocker. L-type calcium channels mediate the influx of calcium during depolarization in arterial smooth muscle. Experiments in anesthetized rats and dogs show that clevidipine reduces mean arterial blood pressure by decreasing systemic vascular resistance. Clevidipine does not reduce cardiac filling pressure (pre-load), confirming lack of effects on the venous capacitance vessels.
Source: US FDA prescribing information
For intravenous use: Cleviprex is intended for intravenous use. Titrate Cleviprex to achieve the desired blood pressure reduction. Individualize dosage depending on the blood pressure response of the patient and the goal blood pressure. Monitoring: Monitor blood pressure and heart rate during infusion, and until vital signs stabilize. Initial dose: Initiate intravenous infusion of Cleviprex at 1- 2 mg/hour. Dose titration: Double the dose at short (90 second) intervals initially. As the blood pressure approaches goal, increase the dose by less than doubling and lengthen the time between dose adjustments to every 5-10 minutes. An approximately 1-2 mg/hour increase will generally produce an additional 2-4 mmHg decrease in systolic pressure. Maintenance dose: Most patients will achieve the desired therapeutic response at approximately 4-6 mg/hour.
Source: US FDA prescribing information
Cleviprex is contraindicated in patients with: Allergy to soy or eggs. Defective lipid metabolism. Severe aortic stenosis Known Allergy Cleviprex is contraindicated in patients with allergies to soybeans, soy products, eggs, or egg products. Defective Lipid Metabolism Cleviprex is contraindicated in patients with defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia. Severe Aortic Stenosis Cleviprex is contraindicated in patients with severe aortic stenosis because afterload reduction can be expected to reduce myocardial oxygen delivery.
Source: US FDA prescribing information
Maintain aseptic technique. Discard unused portion 12 hours after stopper puncture. Hypotension and reflex tachycardia are potential consequences of rapid upward titration of Cleviprex. Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure. Monitor heart failure patients carefully. Cleviprex gives no protection against the effects of abrupt beta-blocker withdrawal. Patients who receive prolonged Cleviprex infusions and are not transitioned to other antihypertensive therapies should be monitored for the possibility of rebound hypertension for at least 8 hours after the infusion is stopped.
Source: US FDA prescribing information
The following risk is discussed elsewhere in the labeling: Hypotension and Reflex Tachycardia Most common adverse reactions (>2%) are headache, nausea, and vomiting.
Source: US FDA prescribing information
Store vials refrigerated at 2-8°C (36-46°F). Do not freeze. Vials in cartons may be transferred to 25°C (77°F, USP controlled room temperature) for a period not to exceed 2 months. Upon transfer to room temperature, mark vials in cartons “This product was removed from the refrigerator on _/_/_ date. It must be used or discarded 2 months after this date or the labeled expiration date (whichever date comes first).” Do not return to refrigerated storage after beginning room temperature storage.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Clevidipine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Cleviprex 25 mg/50 mL injectable emulsionIntravenous Cold chain | Chiesi | US FDA | Available on request |
| Cleviprex 50 mg/100 mL injectable emulsionIntravenous Cold chain | Chiesi | US FDA | Available on request |
| Cleviprex 125 mg/250 mL injectable emulsionIntravenous Cold chain | Fresenius Kabi Austria | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 1 August 2008 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Clevidipine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Clevidipine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Clevidipine, including Cleviprex.
Yes. The US FDA first approved Clevidipine on 1 August 2008, according to Drugs@FDA.
At least one listed presentation of Clevidipine must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Clevidipine is classified under ATC code C08CA16 (Clevidipine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.